U
EastWest Bioscience Inc.
HBOSF
OTC PK
D
Sell
7/3/2023Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D- from E+ on 7/3/2023 due to an increase in the volatility index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D- from E+ on 7/3/2023 due to an increase in the volatility index.
E
Sell
5/18/2023Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D- on 5/18/2023 due to a large decline in the total return index, volatility index and efficiency index.
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D- on 5/18/2023 due to a large decline in the total return index, volatility index and efficiency index.
D
Sell
2/21/2023Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 2/21/2023 due to a decline in the volatility index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 2/21/2023 due to a decline in the volatility index.
D
Sell
2/3/2023Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 2/3/2023 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 2/3/2023 due to an increase in the volatility index and total return index.
D
Sell
1/13/2023Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 1/13/2023 due to a decline in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 1/13/2023 due to a decline in the volatility index and total return index.
D
Sell
12/27/2022Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 12/27/2022 due to an increase in the total return index and volatility index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 12/27/2022 due to an increase in the total return index and volatility index.
D
Sell
12/6/2022Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 12/6/2022 due to a decline in the volatility index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 12/6/2022 due to a decline in the volatility index.
D
Sell
11/18/2022Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 11/18/2022 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 11/18/2022 due to an increase in the volatility index and total return index.
D
Sell
10/24/2022Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 10/24/2022 due to a decline in the volatility index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 10/24/2022 due to a decline in the volatility index.
D
Sell
10/7/2022Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 10/7/2022 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 10/7/2022 due to an increase in the volatility index and total return index.
D
Sell
9/22/2022Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 9/22/2022 due to a decline in the volatility index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 9/22/2022 due to a decline in the volatility index.
D
Sell
9/7/2022Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 9/7/2022 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 9/7/2022 due to an increase in the volatility index and total return index.
D
Sell
6/30/2022Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 6/30/2022 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 126.85% from $1.65M to -$442.9, earnings per share declined from $0.0165 to -$0.0044, and total capital declined 8.84% from $5.04M to $4.59M.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 6/30/2022 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 126.85% from $1.65M to -$442.9, earnings per share declined from $0.0165 to -$0.0044, and total capital declined 8.84% from $5.04M to $4.59M.
D
Sell
4/18/2022Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 4/18/2022 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 527.53% from -$385.8 to $1.65M, and total capital increased 244.31% from $1.46M to $5.04M.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 4/18/2022 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 527.53% from -$385.8 to $1.65M, and total capital increased 244.31% from $1.46M to $5.04M.
D
Sell
12/6/2021Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 12/6/2021 due to a major decline in the growth index and volatility index. Operating cash flow declined 709.94% from $48.3 to -$294.6, earnings per share declined from -$0.0013 to -$0.0078, and EBIT declined 462.39% from -$158.2 to -$889.7.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 12/6/2021 due to a major decline in the growth index and volatility index. Operating cash flow declined 709.94% from $48.3 to -$294.6, earnings per share declined from -$0.0013 to -$0.0078, and EBIT declined 462.39% from -$158.2 to -$889.7.
D
Sell
11/9/2021Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from E+ on 11/09/2021.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from -4.7 to -4.6.
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from -4.7 to -4.6.
D
Sell
12/30/2020Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 12/30/2020 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0032 to -$0.0024.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 12/30/2020 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0032 to -$0.0024.
D
Sell
10/28/2020Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 10/28/2020 due to a decline in the total return index and volatility index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 10/28/2020 due to a decline in the total return index and volatility index.
D
Sell
10/13/2020Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 10/13/2020 due to an increase in the volatility index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 10/13/2020 due to an increase in the volatility index.
D
Sell
9/28/2020Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 9/28/2020 due to a decline in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 9/28/2020 due to a decline in the volatility index and total return index.
D
Sell
9/11/2020Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 9/11/2020 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 9/11/2020 due to an increase in the volatility index and total return index.
D
Sell
8/27/2020Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 8/27/2020 due to a decline in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 8/27/2020 due to a decline in the volatility index and total return index.
D
Sell
8/7/2020Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 8/7/2020 due to an increase in the volatility index and total return index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from D- on 8/7/2020 due to an increase in the volatility index and total return index.
D
Sell
7/23/2020Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 7/23/2020 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0004 to -$0.0032, total revenue declined 50.54% from $203.6 to $100.7, and operating cash flow declined 4.91% from -$38.7 to -$40.6.
EastWest Bioscience Inc. (HBOSF) was downgraded to D- from D on 7/23/2020 due to a large decline in the growth index and solvency index. Earnings per share declined from -$0.0004 to -$0.0032, total revenue declined 50.54% from $203.6 to $100.7, and operating cash flow declined 4.91% from -$38.7 to -$40.6.
D
Sell
5/1/2020Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D from E+ on 5/1/2020 due to a large increase in the solvency index, valuation index and growth index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D from E+ on 5/1/2020 due to a large increase in the solvency index, valuation index and growth index.
E
Sell
4/6/2020Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D- on 4/6/2020 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 10.23 to 12.96.
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D- on 4/6/2020 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 10.23 to 12.96.
D
Sell
3/23/2020Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index.
EastWest Bioscience Inc. (HBOSF) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index.
E
Sell
2/11/2020Downgrade
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D- on 2/11/2020 due to a significant decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 3.2 to 10.23, the quick ratio declined from 0.17 to 0.1, and total capital declined 16.36% from $1.93M to $1.61M.
EastWest Bioscience Inc. (HBOSF) was downgraded to E+ from D- on 2/11/2020 due to a significant decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 3.2 to 10.23, the quick ratio declined from 0.17 to 0.1, and total capital declined 16.36% from $1.93M to $1.61M.
D
Sell
9/3/2019Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to D- from E on 9/3/2019 due to an increase in the efficiency index, growth index and valuation index. Operating cash flow increased 48.56% from -$981.2 to -$504.7, total revenue increased 31.41% from $273.5 to $359.4, and earnings per share increased from -$0.0085 to -$0.0078.
EastWest Bioscience Inc. (HBOSF) was upgraded to D- from E on 9/3/2019 due to an increase in the efficiency index, growth index and valuation index. Operating cash flow increased 48.56% from -$981.2 to -$504.7, total revenue increased 31.41% from $273.5 to $359.4, and earnings per share increased from -$0.0085 to -$0.0078.
E
Sell
6/3/2019Upgraded
EastWest Bioscience Inc. (HBOSF) was upgraded to E from E- on 06/03/2019.
EastWest Bioscience Inc. (HBOSF) was upgraded to E from E- on 06/03/2019.
E
Sell
3/29/2019None
EastWest Bioscience Inc. (HBOSF) was downgraded to E- from U on 03/29/2019.
EastWest Bioscience Inc. (HBOSF) was downgraded to E- from U on 03/29/2019.
